Posted: Tuesday, August 30, 2022
For patients with prostate cancer, the actin-binding protein fascin-1 (FSCN1) may serve as a biomarker for both diagnostic and treatment modalities, according to a study published in Evidence-Based Complementary and Alternative Medicine. FSCN1 activates the anti–yes-associated protein/antitranscriptional coactivators with the PDZ-binding motif (YAP/TAZ) signaling pathway, leading to critical survival processes in prostate cancer cells including invasion, migration, epithelial-mesenchymal transition, and glycolysis, explained Zhanshu Ma, MD, of the Affiliated Hospital of Chifeng University, China, and colleagues.
A total of 40 patients with prostate cancer were recruited for the study. Tissue samples were obtained from cancerous tissue (n = 20) and histologically normal tissue adjacent to the tumor (n = 20). Additionally, human prostate cancer cells and human normal prostate epithelial cells were cultured. Tissue samples were subjected to real-time quantitative polymerase chain reaction to measure messenger RNA expression levels of FSCN1. The transwell test, scratch test, and metabolic assays were employed to assess the invasion abilities, migration abilities, and glucose consumption of cells, respectively. Furthermore, Western blot analysis was used to assess signaling pathway–related protein expression.
The authors reported significantly increased expression of FSCN1 in prostate cancer cells and tissues. They speculated that the invasion, migration, epithelial-mesenchymal transition, and glycolysis of prostate cancer cells may be enhanced by the overexpression of and inhibited by the underexpression of FSCN1. Moreover, they identified evidence supporting the role of FSCN1 in the activation of the YAP/TAZ signaling pathway, which may lead to the progression of prostate cancer.
Disclosure: For full disclosures of the study authors, visit hindawi.com.